<section class="hero">
  <div class="container">
    <div class="category">The Regulatory Series</div>
    <h1><em>503A</em> vs <em>503B</em></h1>
    <p class="dek">Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Walk into a CVS in any city and ask for a vial of semaglutide compounded for your specific dose. You will be told, with some bewilderment, that they do not do that. They cannot do that. The chemistry is straightforward. The reason it cannot happen at a chain pharmacy is not chemistry. It is law.</p>

    <p>Two sections of the Federal Food, Drug, and Cosmetic Act, written years apart and forced to grow up by an outbreak that killed sixty-four people, decide where your peptide can be made and who is allowed to make it. They are called Section 503A and Section 503B. Together they describe the entire universe of compounded medications in the United States. Together they decide whether the peptide in your refrigerator is medicine or something else.</p>

    <h2>What "compounding" actually means</h2>

    <p>A compounded drug is a medication prepared for a specific patient by a licensed pharmacy, usually because the manufactured version does not exist or does not meet that patient's needs. A child who cannot swallow a tablet might need the drug in liquid form. A patient allergic to a dye in a commercial product might need a dye-free version. A peptide therapy, dosed precisely for one patient and not produced as a finished commercial drug, is compounded.</p>

    <p>This is an old practice. American pharmacy was almost entirely compounding until industrial pharmaceutical manufacturing took over in the twentieth century. What modern law had to do was draw clear lines around it: who can compound, for whom, at what scale, and to what standards. Section 503A and Section 503B are those lines.</p>

    <h2>1997, 2012, 2013</h2>

    <p>The first formal compounding framework was the FDA Modernization Act of 1997. It carved out an exemption from full drug-manufacturer regulation for pharmacies that compounded individual prescriptions. That exemption became Section 503A. For the next fifteen years, it described essentially all of legitimate compounding in the United States.</p>

    <p>In 2012, a Massachusetts pharmacy called the New England Compounding Center shipped contaminated methylprednisolone injections to clinics in twenty-three states. Sixty-four patients died from fungal meningitis. Seven hundred and ninety-three more became seriously ill. The pharmacy's owner was eventually convicted on federal charges. The outbreak made it clear that 503A had been written for a smaller world, one in which compounding pharmacies prepared individual prescriptions rather than industrial-scale batches shipped in bulk.</p>

    <p>Congress responded the next year with the Drug Quality and Security Act of 2013. The law added a second category, Section 503B, for facilities that compound at scale without patient-specific prescriptions. The two sections, taken together, became the law that governs every legitimate compounded vial in the country.</p>

    
    <div class="timeline-wrap">
      <svg viewBox="0 0 680 220" xmlns="http://www.w3.org/2000/svg" aria-label="The regulatory history of compounded drugs in the United States">
        
        <line x1="60" y1="100" x2="620" y2="100" stroke="#730e07" stroke-width="1" opacity="0.5"></line>

        
        <g>
          <circle cx="60" cy="100" r="6" fill="#730e07"></circle>
          <text x="60" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1997</text>
          <text x="60" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">FDAMA</text>
          <text x="60" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Section 503A</text>
          <text x="60" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">established</text>
        </g>

        
        <g>
          <circle cx="246" cy="100" r="6" fill="#730e07"></circle>
          <text x="246" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">2012</text>
          <text x="246" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">NECC OUTBREAK</text>
          <text x="246" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">64 deaths,</text>
          <text x="246" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">23 states</text>
        </g>

        
        <g>
          <circle cx="434" cy="100" r="6" fill="#730e07"></circle>
          <text x="434" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">2013</text>
          <text x="434" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">DQSA</text>
          <text x="434" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Section 503B</text>
          <text x="434" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">established</text>
        </g>

        
        <g>
          <circle cx="620" cy="100" r="8" fill="#730e07" stroke="#faf6f0" stroke-width="2"></circle>
          <circle cx="620" cy="100" r="14" fill="none" stroke="#730e07" stroke-width="1" opacity="0.4"></circle>
          <text x="620" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="600" fill="#730e07">Today</text>
          <text x="620" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">TWO-TIER</text>
          <text x="620" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">compounding</text>
          <text x="620" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">framework</text>
        </g>
      </svg>
      <div class="timeline-caption">How the framework arrived at its current shape</div>
    </div>

    <h2>503A: the patient-specific compounder</h2>

    <p>A 503A pharmacy compounds medications for individual named patients with valid prescriptions. Every vial leaving the pharmacy carries a prescription label showing the patient's name, the prescriber, the dose, and the expiration date. State boards of pharmacy regulate 503A pharmacies as their primary oversight body. The FDA also has authority, especially when interstate shipping crosses certain volume thresholds, but day-to-day inspection happens at the state level.</p>

    <p>Sterile compounded products, including all injectable peptides, must be made under USP General Chapter 797, which sets requirements for cleanroom design, air-quality testing, sterilization, personnel training, and final-product release. Each batch is documented. Each prescription is filled against a specific patient's record. This is where the great majority of compounded peptides for individual patients come from in the United States.</p>

    <h2>503B: the outsourcing facility</h2>

    <p>A 503B facility, formally called an outsourcing facility, compounds at scale without patient-specific prescriptions. The customer is typically a clinic or hospital that needs office-stock supply rather than a single named patient. To make this legal, 503B facilities must operate under Current Good Manufacturing Practice standards, the same framework used by industrial pharmaceutical manufacturers. They are inspected by the FDA directly, on a published schedule, the way a manufacturer is inspected.</p>

    <p>503B facilities can ship interstate without the volume limits that apply to 503A pharmacies. They register voluntarily with the FDA and submit production reports. The standards are higher, the federal oversight is more direct, and the volume per facility is much larger.</p>

    
    <div class="comparison">
      <div class="comparison-header">Side by side</div>
      <div class="comp-grid">
        <div class="comp-card">
          <div class="comp-num">503A</div>
          <div class="comp-tagline">Patient-Specific</div>
          <div class="comp-row">
            <div class="comp-label">Who it serves</div>
            <div class="comp-value">An individual patient with a valid prescription written for that patient.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Standards</div>
            <div class="comp-value">USP General Chapter 797 for sterile, 795 for non-sterile preparations.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Primary regulator</div>
            <div class="comp-value">State board of pharmacy, with FDA authority above certain thresholds.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Typical use</div>
            <div class="comp-value">Personalized peptide therapy, custom dosing, allergy-driven reformulation.</div>
          </div>
        </div>
        <div class="comp-card">
          <div class="comp-num">503B</div>
          <div class="comp-tagline">Outsourcing Facility</div>
          <div class="comp-row">
            <div class="comp-label">Who it serves</div>
            <div class="comp-value">Clinics and hospitals that need office stock, without patient-specific prescriptions.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Standards</div>
            <div class="comp-value">Current Good Manufacturing Practice (CGMP), the same standard as a drug manufacturer.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Primary regulator</div>
            <div class="comp-value">FDA, directly, with scheduled inspections and production reporting.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Typical use</div>
            <div class="comp-value">Bulk office stock, in-clinic injectables, surgical-suite preparations.</div>
          </div>
        </div>
      </div>
    </div>

    <h2>Why the distinction matters for your prescription</h2>

    <p>Two practical things follow from this legal architecture. First, your peptide prescription has to be written specifically for you, by a licensed clinician, to be filled at a 503A pharmacy. There is no "self-prescribed" route, and the absence of a prescription is what legally distinguishes a compounded medication from a "research grade" chemical. Second, the pharmacy that fills your prescription has a name, a license, an inspection record, and a state board accountable for its conduct. Any of this can be audited if you want to.</p>

    <p>Both of these are features, not friction. They are the reason a compounded peptide is treated as medicine and the reason your name is on the label.</p>

    
    <div class="pullquote">
      <p>The two short numbers, <span class="mark">503A</span> and <span class="mark">503B</span>, are the entire architecture of legitimate compounded medicine in the United States.</p>
    </div>

    <h2>Where pru sits in this framework</h2>

    <p>At <span class="brand-mark">pru</span>, every prescription is filled at a state-licensed 503A pharmacy that we have evaluated in detail. The pharmacy has a name. The pharmacy has a license number. The pharmacy is inspected by its state board. Each batch ships with a Certificate of Analysis. We chose 503A as the framework for individual patient prescriptions because that is what the law was designed for, and because the level of patient-specific care it requires is the level we want delivered to every <span class="brand-mark">pru</span> patient.</p>

    <p>The two short numbers are the entire architecture. They explain why CVS does not sell peptides, why your prescription has to be written a specific way, and why the pharmacy filling it is named, licensed, and accountable. The next time you read a vial label, those numbers are the reason it says what it says.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>U.S. Food and Drug Administration. <em>Compounding and the FDA: Questions and Answers.</em> fda.gov/drugs/human-drug-compounding.</li>
      <li>Drug Quality and Security Act of 2013. <em>Public Law 113-54.</em> Codified at 21 U.S.C. §§ 353a (Section 503A) and 353b (Section 503B).</li>
      <li>FDA Modernization Act of 1997. <em>Public Law 105-115.</em> Original statutory creation of the 503A compounding exemption.</li>
      <li>Smith, R. M., Schaefer, M. K., Kainer, M. A., et al. (2013). "Fungal Infections Associated with Contaminated Methylprednisolone Injections." <em>New England Journal of Medicine</em> 369: 1598–1609. (Canonical publication on the 2012 NECC outbreak.)</li>
      <li>United States Pharmacopeia. <em>General Chapter 797: Pharmaceutical Compounding, Sterile Preparations.</em> Current revision.</li>
      <li>United States Pharmacopeia. <em>General Chapter 795: Pharmaceutical Compounding, Non-sterile Preparations.</em> Current revision.</li>
      <li>U.S. Food and Drug Administration. <em>Registered Outsourcing Facilities (Section 503B).</em> fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.</li>
      <li>U.S. Food and Drug Administration. <em>Current Good Manufacturing Practice (CGMP) Regulations.</em> 21 CFR Parts 210 and 211.</li>
      <li>Centers for Disease Control and Prevention. <em>Multistate Fungal Meningitis Outbreak Investigation, 2012–2013.</em> cdc.gov.</li>
    </ol>
  </div>
</section>

Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all.

503A vs 503B

Stay in the loop.